For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Triptorelin Acetate is a peptide formulation for injection that was initially developed and continues to be used mainly in the treatment of advanced metastatic prostate cancer. Additional indications developed subsequently include the treatment of uterine fibroids (a benign tumour of muscle tissues in the uterus), endometriosis (proliferation of endometrial tissue, the mucous membrane that lines the uterine wall outside the reproductive tract) prior to surgery or when surgery is not deemed appropriate, as well as early onset puberty and female infertility (in vitro fertilisation).
Scope of the Report:
The global production of triptorelin acetate is about 2770 k units in 2015, the production region is mainly concentrated in Europe, the biggest three countries are France, Germany and Ireland. The top two companies are Ipsen and Ferring, they occupies about 95% market shares;
Although the production region is very concentration, the consumption region is very dispersion, in 2015, the largest consumption Europe is about 38%, the North America consumes about 12% market share, China occupies about 9% market share, Japan occupies about 8.29% market share.
The production and consumption region is different, the production region is mainly concentrated in Europe, the consumption region is dispersion in all over the world; the countries which do not include in the Europe mainly depends on import.
The worldwide market for Triptorelin Acetate is expected to grow at a CAGR of roughly 4.7% over the next five years, will reach 600 million US$ in 2024, from 460 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Triptorelin Acetate in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- Ipsen
- Ferring
- Chengdu Tiantaishan
- TECNOFARMA
- Changchun Gensci
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- 0.1 mg
- 3 mg
- 11.25 mg
Market Segment by Applications, can be divided into
- Male Disease
- Female Disease
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Triptorelin Acetate product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Triptorelin Acetate, with price, sales, revenue and global market share of Triptorelin Acetate in 2017 and 2018.
Chapter 3, the Triptorelin Acetate competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Triptorelin Acetate breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Triptorelin Acetate market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Triptorelin Acetate sales channel, distributors, customers, research findings and conclusion, appendix and data source.